Several economic benefits stem from engaging in care soon after HIV transmission and maintaining viral load suppression, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University College of Pharmacy.
Less hospitalization, health care dollars spent, and missed days of work, as well as better outcomes, especially for patients engaged in care soon after transmission, are all economic benefits from maintaining viral load suppression when living with HIV, noted Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University College of Pharmacy who practices at Northwestern Medicine's Infectious Disease Center in Chicago.
Transcript
What are the economic benefits of maintaining viral load suppression?
There's a lot of literature confirming that patients with an undetectable viral load have less hospitalizations and better outcomes than patients with a detectable viral load. And patients that get into care early after transmission, so if we can diagnose them early in the disease course, they also spend less health care dollars overall, both indirect and directly.
Direct benefits to the patient with having that stronger immune system, they’re potentially going to the doctor less often, they're having less issues, no opportunistic infections. And then indirectly over the patient's lifetime, if they're feeling better and have a better immune system, they have less missed days of work.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512